Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age
Clinical trial NCT03102034 · COMPLETED
Trial details
- NCT number
- NCT03102034
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-04-06
- Primary completion
- 2018-05-25
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.